Ptc Therapeutics (PTCT) Revenue (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Revenue of $360.5 million for Q2 2026, up 101.55% year-over-year from $178.9 million in Q2 2025, and up 32.28% quarter-over-quarter from $272.6 million in Q1 2026.
Ptc Therapeutics (PTCT) Revenue (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Revenue history runs 15 years deep, the most recent figure standing at $360.5 million for Q2 2026.
- In Q2 2026, Revenue rose 101.55% year-over-year to $360.5 million; the TTM figure through Jun 2026 stood at $1.0 billion (down 42.84% YoY), while the FY2025 annual figure was $1.7 billion, up 114.51% from the prior year.
- Revenue for Q2 2026 stood at $360.5 million, up from $272.6 million in the prior quarter.
- The five-year high for Revenue was $1.2 billion in Q1 2025, with the low at $148.7 million in Q1 2022.
- The 5-year median for Revenue is $211.0 million (2025), against an average of $271.8 million.
- The sharpest annual moves came in 2025 and 2026: Revenue surged 459.73% in 2025, then tumbled 76.83% in 2026.
- Ptc Therapeutics' Revenue stood at $167.4 million in 2022, then surged by 83.41% to $307.1 million in 2023, then slumped by 30.58% to $213.2 million in 2024, then retreated by 22.75% to $164.7 million in 2025, then jumped by 118.92% to $360.5 million in 2026.
- Business Quant data shows PTCT's Revenue at $360.5 million in Q2 2026, $272.6 million in Q1 2026, and $164.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 360.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 360.52 Mn |
| Mar 31, 2026 | 272.55 Mn |
| Dec 31, 2025 | 164.68 Mn |
| Sep 30, 2025 | 211.01 Mn |
| Jun 30, 2025 | 178.88 Mn |
| Mar 31, 2025 | 1.18 Bn |
| Dec 31, 2024 | 213.17 Mn |
| Sep 30, 2024 | 196.79 Mn |
| Mar 31, 2024 | 210.12 Mn |
| Dec 31, 2023 | 307.06 Mn |
| Sep 30, 2023 | 196.58 Mn |
| Jun 30, 2023 | 213.81 Mn |
| Mar 31, 2023 | 220.38 Mn |
| Dec 31, 2022 | 167.41 Mn |
| Sep 30, 2022 | 217.13 Mn |
| Jun 30, 2022 | 165.53 Mn |
| Mar 31, 2022 | 148.74 Mn |
| Dec 31, 2021 | 165.23 Mn |
| Sep 30, 2021 | 138.74 Mn |
| Jun 30, 2021 | 116.68 Mn |